Nerviano Medical Sciences S.r.l.

Basilea Pharmaceutica Ag

Emergent Product Development Gaithersburg Inc.

Evolva Sa

Pfizer Italia S.r.l.

Basilea Pharmaceuticals Ag

Patrick Roussel

Maria Gabriella Brasca

Paolo Pevarello

Marcella Nesi

Paolo Orsini

Daniele Fancelli

Anna Vulpetti

Raffaella Amici

Fabrizio Orzi

Peter Schneider

Jutta Heim

Christian Bartels

Daniel Milligan

Glenn E Dale

Franck Hubert Danel

Berangere Gaucher

Yaoquan Liu

Eric Desarbre

Malcolm G P Page

Bérangère Gaucher

Bérangére Gaucher

Glen Dale

Malcom G P Page

Malcolm GP Page

Disclosed herein are compounds of Formula I 

2-pyridone antimicrobial compositions

This invention provides novel 4-oxoquinolizine compounds and their uses for a series of broad-spectrum antibiotics having no cross-resistance to existing or emerging classes of antibiotics. In addition the novel 4-oxoquinolizine compounds are useful against CDC Category A and B pathogens. The invention also provides pharmaceutical compositions comprising certain 4-oxoquinolizines in combination with subinhibitory concentrations of polymyxin B against clinical isolates which are resistant to quinolones, carbapenems and other antimicrobial agents.

Antimicrobial 4-oxoquinolizines

This invention provides novel 4-oxoquinolizine compounds and their uses for a series of broad-spectrum antibiotics having no cross-resistance to existing or emerging classes of antibiotics. In addition the novel 4-oxoquinolizine compounds are useful against CDC Category A and B pathogens The invention also provides pharmaceutical compositions comprising certain 4-oxoquinolizines in combination with subinhibitory concentrations of polymyxin B against clinical isolates which are resistant to quinolones, carbapenems and other antimicrobial agents.

A pharmaceutical composition, comprising a combination of an antibiotically active compound of the formula (I): with a &#x3b2;-lactamase inhibitor of one of the formulae (II) to (XIII) are active against Gram-negative bacteria, in particular such bacteria which have become resistant against antibiotics such as aztreonam, carumonam and tigemonam. Optionally the compositions may comprise another &#x3b2;-lactamase inhibitor of one of the formulae (II) to (XIII), particularly of formula (V) or formula (VI).

Useful combinations of monobactam antibiotics with beta-lactamase inhibitors

The antibacterial compound of formula I wherein

Bicyclic antibiotics

Described are a series of 2-pyridone compounds as a potent and selective new class of type II topoisomerase inhibitors with broad-spectrum antimicrobial activity having the general formula (I); where R1, R2, X, and Y are defined herein Such compounds can be used in methods for treating an infection caused by a gram-positive pathogen, a gram-negative pathogen, or a drug-resistant strains thereof. 

New monobactam antibiotics compounds which contain an 3-amino-azetidin-2-one ring and are active against gram-negative bacteria, wherein the compounds include the compound 2-(2-amino-thiazol-4-yl)-2-[(Z)-(1H,4H-1,5-dihydroxy-4-oxo-pyridin-2-yl)methoxyimino]-N-[3(S)-1-oxysulfonyl-2,2-dimethyl-4-oxo-azetidin-3-yl]acetamide.

Compounds represented by formula (Ia) or (Ib) and wherein R and Rare as defined in the description, and pharmaceutically acceptable salts thereof, are disclosed; the said compounds are useful in the treatment of cell cycle proliferative disorders, e.g. cancer, associated with an altered cell cycle dependent kinase activity.

Substituted pyrrolo-pyrazole derivatives as kinase inhibitors

A new class of pyrazolo derivative compounds having the formula where R and Rhave the meanings given herein. The pyrazolo derivative compounds are useful in treating cell proliferative disorders caused by and/or associated with an altered cell cycle dependent kinase activity in mammals. The compounds may be provided in pharmaceutical compositions or in a kit.

Growing community of inventors

Mulhouse, France

Patrick Roussel